The researchers confirms that the technology has passed through all the necessary validation stages, from analytical to bioanalytical to clinical evaluation, progressing through the required Technology Readiness Levels (TRL). They note that further large-scale patient sample analysis in diverse clinical settings, along with robust prototyping, will smoothen the pathway to technology transfer and commercialisation in the near- and mid-term future.

The team comprises Prof. V.V. Raghavendra Sai, Dr. Ratan Kumar Chaudhary (Department of Applied Mechanics and Biomedical Engineering, IIT Madras), Dr. Narayanan Madaboosi (Department of Biotechnology, IIT Madras), Dr. Jitendra Satija (Centre for Nanobiotechnology, Vellore Institute of Technology), Dr. Balaji Nandagopal, and Dr. Ramprasad Srinivasan (Sri Sakthi Amma Institute of Biomedical Research, Sri Narayani Hospital & Research Centre, Vellore).

According to the researchers, the P-FAB-based POF platform offers transformative technology not only for detecting pre-eclampsia but also for detecting other communicable and non-communicable diseases. Importantly, the technology is simple, cost-effective, rapid, and requires only a small sample volume (30 µL or a droplet). Furthermore, it eliminates the need for harsh chemicals and utilizes recyclable POF, making it both environmentally and user-friendly. This makes the technology suitable for use in remote and resource-limited settings.

In India, approximately 8–10% of pregnancies are affected by pre-eclampsia. A 2022 study found that among 28,226 pregnant women, 13.8% had non-severe pre-eclampsia, and 3.19% had severe pre-eclampsia, excluding cases lost to follow-up. 

Adblock test (Why?)